OrbiMed buys 625K BlossomHill IPO shares at $16
Rhea-AI Filing Summary
For BlossomHill Therapeutics, Inc. (BLSM), director Carl L. Gordon, through OrbiMed-related entities, reported automatic conversion of 1,039,996 shares of Series A Preferred Stock and 1,049,283 shares of Series B Preferred Stock into the same number of BlossomHill common shares upon the closing of the company’s initial public offering on August 10, 2026, without payment of consideration. In addition, OrbiMed Private Investments VIII, LP purchased 625,000 BlossomHill common shares in the IPO at $16.00 per share, reported as indirectly owned. The filing states that OrbiMed entities may be deemed to have voting and investment power over these securities, and that Carl L. Gordon, OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC each disclaim beneficial ownership except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 625,000 shares
Net Buy
5 txns
Insider
GORDON CARL L
Role
Director
Bought
625,000 shs ($10.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Preferred Stock F1, F3, F4 | 1,039,996 | $0.00 | $0.00 |
| Conversion | Series B Preferred Stock F1, F3, F4 | 1,049,283 | $0.00 | $0.00 |
| Conversion | Common Stock F1, F3, F4 | 1,039,996 | -- | -- |
| Conversion | Common Stock F1, F3, F4 | 1,049,283 | -- | -- |
| Purchase | Common Stock F2, F3, F4 | 625,000 | $16.00 | $10.00M |
Holdings After Transaction:
Series A Preferred Stock — 0 contracts (Indirect, See footnotes);
Series B Preferred Stock — 0 contracts (Indirect, See footnotes);
Common Stock — 2,714,279 shares (Indirect, See footnotes)
Footnotes (4)
- F1. Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date.
- F2. Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
- F3. These securities are held directly by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
- F4. Each of the Reporting Person, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VIII is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Key Figures
Series A Preferred converted: 1,039,996 shares
Series B Preferred converted: 1,049,283 shares
Common shares from conversion: 2,089,279 shares
+3 more
6 metrics
Series A Preferred converted
1,039,996 shares
Automatically converted into BlossomHill common stock upon IPO closing on August 10, 2026
Series B Preferred converted
1,049,283 shares
Automatically converted into BlossomHill common stock upon IPO closing on August 10, 2026
Common shares from conversion
2,089,279 shares
Total BlossomHill common shares issued from Series A and B Preferred conversion
Common shares purchased in IPO
625,000 shares
BlossomHill common stock purchased by OrbiMed Private Investments VIII, LP
IPO purchase price
$16.00 per share
Price paid for the 625,000 BlossomHill common shares purchased in the IPO
Derivative exercises
2,089,279 shares
Total underlying BlossomHill common shares from preferred stock conversions recorded as derivative transactions
Key Terms
Series A Preferred Stock, initial public offering, beneficial ownership, pecuniary interest, +1 more
5 terms
Series A Preferred Stock financial
"Each share of Series A Preferred Stock and Series B Preferred Stock"
Series A preferred stock is a type of ownership share in a company that gives investors certain advantages, such as priority in receiving profits or getting their money back if the company is sold or goes bankrupt. It is often issued during early funding stages to attract investors by offering more security than common shares. This stock matters to investors because it provides a safer way to invest while still holding potential for future gains.
initial public offering financial
"converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
beneficial ownership financial
"may be deemed to have beneficial ownership over such securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of its pecuniary interest therein, if any"
voting power and investment power financial
"may be deemed to have voting power and investment power over the securities"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did BLSM director Carl L. Gordon report on August 10, 2026?
Carl L. Gordon reported automatic conversion of BlossomHill preferred stock into common stock and a purchase of 625,000 common shares at $16.00 per share in the company’s IPO, all held indirectly through OrbiMed-related investment entities with beneficial ownership disclaimed except for any pecuniary interest.
Was a Rule 10b5-1 trading plan indicated for these BLSM insider transactions?
The Form 4’s Rule 10b5-1 checkbox is not marked as affirmative for these transactions. The footnotes do not describe any pre-arranged Rule 10b5-1 trading plan, so the report does not characterize the activity as executed under such a plan.
What triggered the conversion of BlossomHill (BLSM) preferred stock reported in this Form 4?
The Series A and Series B Preferred Stock automatically converted into BlossomHill common stock upon closing of the initial public offering on August 10, 2026. The filing states that each preferred share converted into one common share and that no additional consideration was paid for the conversion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
